Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05435248

Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

A Phase 1/2, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10375 Monotherapy in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions Advanced or Metastatic NSCLC

Interventions HS-10375

Updated 4 times since 2022 Last updated: Nov 1, 2024 Started: Mar 2, 2022 Primary completion: Mar 31, 2025 Completion: Mar 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Advanced or Metastatic NSCLC, this trial is actively recruiting participants. The trial is conducted by Jiangsu Hansoh Pharmaceutical Co., Ltd. and has accumulated 4 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Dec 2024 — Present [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jul 2022 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Data source: Jiangsu Hansoh Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China